Follow-up clinical trials will include new pharmacotherapies, such as naltrexone, nalmefene, and acamprosate, combined with standardized behavioral strategies. In sum, we expect findings from genetics research, neuroscience, and medications development to inform the development of increasingly improved treatment strategies. To ensure the acquisition of meaningful results, these studies employ rigorously defined scientific methodologies including random selection and control communities. One excellent example is a recent study nearing completion which may provide a model alcohol use prevention program that can be implemented in communities around the country. The project targets the Class of 1998 and has been ongoing for five years, beginning with students in the sixth grade and following them through grade 10.
Interim results look quite hopeful.
Of great significance is the fact that overall fewer students initiated alcohol use. For instance, past month alcohol use by 8th graders who did not drink in grade 6 was 28 percent lower in program communities than in reference communities. This past year we published and disseminated 75,000 copies of The Physicians' Guide to Helping Patients with Alcohol Problems . DuPont Pharma is also significantly aiding in this effort at their own expense by printing and distributing through their field representatives an additional 60,000 copies to primary care physicians nationwide. In conclusion, alcohol research is progressing rapidly and the scientific advances and opportunities in our field are very encouraging.